Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

NEWS

Lucid Diagnostics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
Monday, 23rd December at 8:01 am
NEW YORK, Dec. 23, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ: PAVM), today announced that it had received written notification from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq") that the Company was eligible for a 180-day extension to regain compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Rule"). The Company now has until June 16, 2025 to meet the requirement.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
1
+0
Translate
Report
797 Views
Comment
Sign in to post a comment